Sun Pharma will have the exclusive right to commercialize Winlevi in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.
Camcevi 42 mg subcutaneous injection is a gonadotropin-releasing hormone agonist indicated for the treatment of adult patients with advanced prostate cancer.